Skip to NavigationSkip to content


Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland

Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to offer a generic version of Gilead’s antiretroviral HIV drug Truvada (emtricitabine and tenofovir disoproxil fumarate) for up to 60% cheaper than the branded treatment.

As Gilead attempts to protect its investment and its market share, the dispute has found its way into the High Court in Dublin. The company is reportedly requesting that the case be placed on the court’s fast-track commercial list, which covers cases of €1 million or more.

Amygdala acquires Gilead’s candidate for addiction treatment

Amygdala Neurosciences, a biopharmaceutical company that develops and commercialises drugs for the treatment of addiction disorders, has agreed an acquisition with Gilead’s GS-6637. The drug is ready to enter Phase 2 trials and brings the drug candidate back to the team that had previously developed the drug, prior to Gilead takeover.

The drug, GS-6637- is a selective ALDH2 inhibitor, that could potentially treat behaviour and substance abuse by changing the mechanism of action associated with dopamine surges and cravings.

Hepatitis C market set for slump as cure rates rise

Objectively, it is the pharmaceutical industries intention to find cures for diseases and to aid patients to live a full life - the hepatitis C market has been so successful in this aim that it now threatens its own existence. The latest report from GlobalData suggests that the hep C market is set to decline and the primary reason for the decline in sales is because cure rates of hep C are so high and so successful.

Gilead makes move in oncology by snaffling Riva from Novartis

Published on: 04/01/17

Gilead Sciences have made an ambitious move to boost its oncology business by appointing current head of global oncology development at Novartis, Alessandro Riva. Riva will join Gilead in the role of senior vice president, haematology and oncology therapeutic area head.

Court of Appeal rules that the NHS can legally fund HIV-prevention drug PrEP

A High Court ruling that NHS England was legally responsible for preventing the spread of HIV has been upheld when taken to the Court of Appeal. The ruling pertains to a measure, known as PrEP, short for pre-exposure prophylaxis, that operates as a preventions strategy in those individuals who are at high risk of infection.

The individuals who are deemed at high risk can be provided with anti-retroviral drug Truvada, sold by Gilead, that acts to reduce the risk of HIV infection by more than 90%.

Gilead quietly drops drugs from line up alongide Q3 results

Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for Gilead, was selonsertib. The drug is an investigation inhibitor of apoptosis signal-regulating kinase 1. Gilead had announced as recently as mid-October that they would pursue development of the drug through to Phase III trials following “encouraging” results.

Gilead’s drug boosted by positive Phase II trials and aims to move forward

Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The drug treats fatty liver disease, which is more commonly known as NASH (non-alcoholic steatohepatitis. The drug was tested alone and alongside Gilead’s experimental anti-fibrotic drug simtuzumab. The treatment was found to reduce liver scarring in the mid-stage trial.

Gilead terminates Phase II/III study for ulcerative colitis antibody

Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative colitis after the drug failed to show sufficient efficacy.

The decision was reached after the Data Monitoring Committee reviewed the experiences of the first 150 of a planned 1,600 trial participants. The committee recommended the termination of the study due to it meeting pre-specified futility and efficacy criteria.

Top Ten articles in the Pharma Industry this week

As we come to the end of another week, we're looking back at an exciting week in the industry; there has been some big industry team-ups and exciting acqusitions, and we finally got to see the end of a saga that we've been covering with bated breath for weeks and months!

10. GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

Partnership seeks EMA approval to oust rival products from Roche and Sanofi.

Gilead appoints former Roche executive

Published on: 09/09/16

Gilead Sciences has hired Rogers Luo as vice president and general manager of commercial operations in China. Luo formerly served as vice president at Shanghai Roche Pharmaceuticals.

His primary remit will be building the company’s commercial operations in China, preparing the potential launch of its hepatitis C and B treatments over the next few years.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches